title: Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study.
abstract: BACKGROUND
  The prognostic value of Doppler myocardial imaging, including myocardial velocity imaging, strain, and strain rate imaging, in patients with primary (AL) amyloidosis is uncertain. The aim of this longitudinal study was to identify independent predictors of survival, comparing clinical data, hematologic and cardiac biomarkers, and standard echocardiographic and Doppler myocardial imaging measures in a cohort of patients with AL amyloidosis.
  
  
  METHODS
  A total of 249 consecutive patients with AL amyloidosis were prospectively enrolled. The primary end point was all-cause mortality, and during a median follow-up period of 18 months, 75 patients (30%) died. Clinical and electrocardiographic data, biomarkers (brain natriuretic peptide and cardiac troponin T) and standard echocardiographic and longitudinal systolic and diastolic Doppler myocardial imaging measurements for 16 left ventricular segments were tested as potential independent predictors of survival.
  
  
  RESULTS
  Age (hazard ratio [HR], 1.03; P = .03), New York Heart Association class III or IV (HR, 2.47; P = .01), the presence of pleural effusion (HR, 1.79; P = .08), brain natriuretic peptide level (HR, 1.29; P = .01), ejection time (HR, 0.99; P = .13), and peak longitudinal systolic strain of the basal anteroseptal segment (HR, 1.05; P = .02) were independent predictors in the final model.
  
  
  CONCLUSIONS
  Multivariate survival analysis identified independent predictors of clinical outcome in patients with AL amyloidosis: New York Heart Association class III or IV, presence of pleural effusion, brain natriuretic peptide level > 493 pg/mL, ejection time < 273 ms, and peak longitudinal systolic basal anteroseptal strain less negative than or equal to -7.5% defined a high-risk group of patients.
authors.affiliation: Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
authors.forename: Diego
authors.initials: D
authors.lastname: Bellavia
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Pellikka
authors.forename: Ghormallah B
authors.initials: GB
authors.lastname: Al-Zahrani
authors.forename: Theodore P
authors.initials: TP
authors.lastname: Abraham
authors.forename: Angela
authors.initials: A
authors.lastname: Dispenzieri
authors.forename: Chinami
authors.initials: C
authors.lastname: Miyazaki
authors.forename: Martha
authors.initials: M
authors.lastname: Lacy
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Scott
authors.forename: Jae K
authors.initials: JK
authors.lastname: Oh
authors.forename: Fletcher A
authors.initials: FA
authors.lastname: Miller
mesh_terms: D000368:Aged; D000686:Amyloidosis / Q000097:blood / Q000150:complications / Q000401:mortality*; D015415:Biomarkers / Q000097:blood; D015150:Echocardiography, Doppler; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality*
chemical_list: D015415:Biomarkers